In this review, factors affecting the QT interval and the methods that are currently in use in the analysis of drug effects on the QT interval duration are overviewed with the emphasis on (population) pharmacokinetic-pharmacodynamic (PK-PD) modeling. Among which the heart rate (HR) and the circadian rhythm are most important since they may interfere with the drug effect and need to be taken into account in the data analysis. The HR effect or the RR interval (the distance between 2 consecutive R peaks) effect is commonly eliminated before any further analysis, and many formulae have been suggested to correct QT intervals for changes in RR intervals. The most often used are Bazett and Fridericia formulae introduced in 1920. They are both based on the power function and differ in the exponent parameter. However, both assume the same exponent for different individuals. More recent fi ndings do not confi rm this assumption, and individualized correction is necessary to avoid under-or overcorrection that may lead to artifi cial observations of drug-induced QT interval prolongation. Despite the fact that circadian rhythm in QT and QTc intervals is a welldocumented phenomenon, it is usually overlooked when drug effects are evaluated. This may result in a false-positive outcome of the analysis as the QTc peak due to the circadian rhythm may coincide with the peak of the drug plasma concentration. In view of these effects interfering with a potential drug effect on the QTc interval and having in mind low precision of QT interval measurements, a preferable way to evaluate the drug effect is to apply a population PK-PD modeling. In the literature, however, there are only a few publications in which population PK-PD modeling is applied to QT interval prolongation data, and they all refer to antiarrhythmic agents. In this review, after the most important sources of variability are outlined, a comprehensive population PK-PD model is presented that incorporates an individualized QT interval correction, a circadian rhythm in the individually corrected QT intervals, and a drug effect. The model application is illustrated using real data obtained with 2 compounds differing in their QT interval prolongation potential. The usefulness of combining data of several studies is stressed. Finally, the standard approach based on the raw observations and formal statistics, as described in the Preliminary Concept paper of the International Conference on Harmonization, is briefl y compared with the method based on population PK-PD modeling, and the advantages of the latter are outlined.
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INTRODUCTION
Since the mid 1980s, evidence has accumulated that several classes of noncardiac drugs signifi cantly prolong the QT interval of the surface electrocardiogram (ECG) and have cardiotoxic potential (risk of life-threatening arrhythmias). 1 , 2 Drug-induced lengthening of the QT interval (stemming from a drug's ability to prolong the cardiac action potential duration) has been associated with the occurrence of ventricular tachyarrhythmias, namely, torsades de pointes (TdP), a polymorphous ventricular arrhythmia that may cause syncope and degenerate into ventricular fi brillation. 3 Although there is an ongoing debate in the literature on the clinical signifi cance of a prolonged QT interval, 4 , 5 it has been found to be a risk factor for sudden death due to cardiac arrest 6 and also for all-cause mortality. 7 , 8 Several interventions by regulatory agencies and/or drug companies have fostered the discussion on the impact of QT-prolonging effects on drug development. 9 While the degree of QT interval prolongation is recognized as an imperfect biomarker for the proarrhythmic risk, there is at least a qualitative relationship between QT interval prolongation and the risk of TdP. Cardiac safety considerations need therefore to be an integral part of phase 1 and 2 studies of every investigational drug. Once proarrhythmic safety of a new drug has been established in early development, large phase 3 studies and postmarketing surveillance can be limited to less strict designs and less laborious investigations (eg, a smaller number of ECGs involved in patient monitoring, less precise approaches to heart rate correction). 2 According to the current practice (at least in some pharmaceutical companies), every compound that enters clinical development receives an electrocardiographic evaluation that typically includes at least one study dedicated to assessing its effect on cardiac repolarization (thorough QT/QTc study 9 ). Given that routine, the question of proper estimation of QT prolongation caused by drugs from clinical study data and correct interpretation becomes a crucial one. This question is fi rmly related to the problem of study design. Due to high inter-and intra-individual variability of QT intervals there is a substantial risk of false-positive or falsenegative study outcomes if the analysis of results is performed without taking into account all of the inherent complexities of the data.
The aim of this review is to give an overview of factors affecting the QT interval and also of the methods that are currently in use in the analysis of drug effects on the QT interval duration with the emphasis on pharmacokineticpharmacodynamic (PK-PD) modeling. Figure 1 shows the intervals typically measured on an ECG. The normal QT interval is from the beginning of the QRS complex to the end of the T-wave. It represents the time between the onset of electrical depolarization of the ventricles and the end of repolarization, that is, it refl ects the duration of individual action potentials in the cardiac myocytes. The QT interval obviously shortens with increasing heart rate (HR) or reducing the RR interval, and this is one of the major sources of QT variability. The QT interval corrected for changes in the RR interval is generally notated QTc (without specifying the details of correction). Other subjectrelated factors potentially affecting the QT or QTc interval 2 are listed below: 10 Furthermore, on average QTc interval is longer in females by ~8 to 10 milliseconds than in males. 11 , 12 Also, females have higher incidence of TdP than men. 13 Obesity is often associated with QTc prolongation and a 10 kg increase in fat mass has been linked to a >5 millisecond increase in QTc. 14 , 15 The QT interval adapts to the changes in HR rather slowly (90% of the adaptation requires ~2 minutes), and this causes the phenomenon known as QT/RR hysteresis. 16 , 17 It is important therefore to ensure that no ECGs are recorded when the heart rate is rising or falling. Specifi cally, if ECGs are recorded while the heart rate is increasing, and the QT interval is not adapted to the faster heart rate, an artifi cially prolonged QTc interval will result because of the mismatch between the RR and QT intervals.
VARIABILITY IN THE QT INTERVAL DURATION
Diffi culty in identifying the end of the T-wave can introduce further variability in the measurement of the QT interval resulting in low precision. 18 Also, manual and automatic measurements may not correlate well. 19 Morphological abnormalities of the T-wave, noise in the signal as well as confusion between the T-and U-wave may easily invalidate automatic measurements. For this reason, no automatic algorithm can be suggested as suffi ciently precise and robust to satisfy the precision required in the assessment of drug cardiac safety. Although some combinations of manual and automatic measurements are permissible when subjected to advanced quality control, it is safer to use manual measurements taken by experienced personnel. 2 These factors have the potential to introduce inconsistencies within and across studies. By contrast, the RR interval is measured with high precision as the R peak on the ECG can be easily positioned ( Figure 1 ).
Taking into account multiple sources of variability in QT intervals differentiating the drug effect is not easy; this requires adequate data analysis methods. PK-PD modeling in general and population modeling in particular 20 , 21 provides validated tools to split the overall variability into components and estimate them with suffi cient precision.
QT-RR RELATIONSHIP
Appropriate correction of QT intervals for changes in RR intervals or HR is an essential element of the evaluation of drug-induced QT prolongation. Since 1920 when 2 pioneering 
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articles appeared 22 , 23 a lot of attention has been paid to fi nding a " magic " formula that provides the ideal correction such that the corrected QT interval is independent of the RR interval (see Malik and Camm for a review 2 ). In spite of the common understanding that such a formula does not exist, most of the authors working in the area of cardiovascular drug safety still use Bazett correction as shown in Equation1:
where RR is in seconds; or the Fridericia correction formula as shown in Equation 2:
More recently, a linear formula has appeared 24 (QT in seconds) as shown in Equation 3 : Figure 2 compares the 3 formulas using as an example a pooled data set comprising QT-RR measurements obtained before treatment in 70 healthy individuals from 4 cardiovascular safety studies. This data set will be used throughout the current review to illustrate various aspects of the QT interval prolongation modeling. Among the 3 formulas, that of Fridericia performs on average quite well; the smoother (loess smooth) is almost horizontal. By contrast, in case of Bazett and linear correction, the loess smoothers are inclined. However, the major problem with these (and other) formulas is that they assume the same correction for every individual, which contradicts with reality; individuals show different QT-RR relationships. 2 , 25 , 26 An obvious solution to this problem is to use an individualized correction. A correction equation is to be fi tted to individual pretherapy QT-RR interval data over a range of heart rates, then individual estimates of parameter(s) of the equation are used to correct on-treatment QT values. Apparently, the fi rst application of this method was in the article by Galeazzi et al 27 in which a linear correction model was fi tted to individual pretreatment data. The authors mentioned the inaccuracy of the Bazett correction that magnifi es drugand heart rate-related effects. 
However, by contrast to the Bazett or Fridericia correction methods, the exponent ␣ is allowed to vary across individuals. The approach based on the individualized correction has been acknowledged by the International Conference on Harmonization (ICH) Preliminary Concept Paper. 9 At present, however, this approach is still not used broadly since collecting suffi ciently large numbers of pretreatment QT interval measurements in each subject needed to estimate individual ␣ with precision is cumbersome.
Mixed-effects modeling provides a practical solution to the problem of individualized QT correction. Taking the model represented by Equation 4, a j-th measured QT interval in an i-th individual, QT ij , can be expressed as follows 31 :
QTc I denotes a corrected QT interval in an i-th individual, ␣ i is a subject-specifi c exponent, and ⑀ ij is a residual normal error. Fitting Equation 5 to the above-mentioned pretreatment data in 70 healthy subjects enables the estimation (through the Bayesian posterior procedure) of individual QTc I , which is a baseline value within a study day, and ␣ i . Figure 3 illustrates the quality of correction achieved by applying mixed-effects modeling as implemented in NON-MEM software (GloboMaX, Ellicott City, MD). 32 First-order conditional estimation (FOCE) method with correction for -⑀ interaction was used. In this fi gure, QT measurements obtained before treatment in randomly selected individuals were corrected using the formula shown in Equation 6 :
and plotted against RR. We will distinguish QTc I , which is a parameter of Equation 5 and those that will follow, and QTc I , which are QT interval measurements individually corrected using Equation 6 . From Figure 3 , between individual variability (BIV) in ␣ is evident, and applying the mixed-effects technique gives an adequate QT correction even with a relatively small number of measurements per individual per study day (10 -15) , which is typical for cardiovascular safety studies.
A recent publication by Li et al 33 also suggests mixed-effects modeling instead of the individual regression. The authors also used the power model, Equation 4 , and applied logtransformation to make it linear. 
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One should stress that an adequate QT correction is a prerequisite for unbiased estimation of drug effects. As shown in Malik 34 and Malik et al, 35 the imprecision in HR correction may lead to artifi cial observations of drug-induced QT interval changes.
PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF QT PROLONGATION
In this section, as well as throughout the whole review only a little attention will be paid to PK aspects of data analysis. The emphasis will be on PD modeling, particularly, on how the drug effect is implemented and statistically evaluated. For brevity, only clinical data modeling will be overviewed; analyses of animal data [36] [37] [38] [39] [40] [41] will not be included.
There are not many publications in the literature in which PK-PD modeling of drug effects on the QT interval was performed. Furthermore, most (if not all) of them consider antiarrhythmic drugs for which the QT interval prolongation is a target pharmacological action. Probably the fi rst publication presenting a form of PK-PD analysis was that by Galeazzi et al 27 who studied the effect of procainamide on the QT interval. The authors did not use any specifi c PD model, but rather developed a PK model for plasma and saliva concentrations during and after intravenous infusion and demonstrated that the corrected QT interval change from a pretreatment value shows hysteresis when plotted against plasma concentration. The hysteresis collapsed after plotting the PD data vs the saliva concentration. Saliva thus played a role of an effect compartment. As one can judge from the graphical presentation the overall shape of the concentration-effect profi les resembled a sigmoid Emax curve; however, PD modeling was not attempted.
Early PK-PD modeling of the concentration-effect relationship was based on individual model fi tting (eg, various formulations of disopyramide were studied 28 , 29 ). QT intervals were individually corrected by fi tting the linear model of the following form to pretreatment data (authors ' notations are used) 29 :
where QT p is the predicted QT interval, b is the intercept on the QT axis, m is the slope of the linear regression, and HR is the mean heart rate determined from the measurements of 20 consecutive cardiac cycles.
Whiting et al 29 developed a PK-PD model using, as the dependent variable, absolute change of the corrected QT interval from baseline. The model included an effect compartment linking the plasma concentration to the pharmacodynamic effect. The selected PD submodel was a linear one:
where E is a drug effect, C e is a model-predicted effect compartment concentration, and m and i are slope and intercept E613 parameters, respectively. There were several versions of PK models tested, and they were fi tted to each individual data set separately. On the contrary, no PD models alternative to the linear one were compared. In a later PK-PD study of disopyramide effect on QTc, 42 the linear PD model was also used, and it was shown that the unbound drug concentration better predicted the response as compared with the total concentration. The equilibration half-life for the effect compartment was ~1.6 minutes.
A linear model similar to that of Equation 8 was used by Holford et al 43 in their study of quinidine effects on QT intervals and other cardiovascular parameters after intravenous and oral administration. QT correction for RR was performed as in Whiting et al 29 using a linear relationship (Equation 7). The intercept parameter of the PD model (Equation 8) was effectively negligible, and the slope parameter differed for the 2 administration routes. The authors believed that the apparent change in the sensitivity to quinidine after an oral dose when compared with an intravenous dose was attributable to one or more active metabolites that were present in higher concentrations at oral administration because of the fi rst-pass metabolism of the drug. The authors mentioned that QTc after placebo administration did not remain constant throughout the day, which may be a consequence of a circadian rhythm (see below). However, no attempt to model circadian variability was made.
Piergies et al 44 investigated PK-PD relationships in QT effects of N-acetylprocainamide infused intravenously to 5 patients with arrhythmias. This was a single-dose study, and the PK-PD model included an effect compartment. The model was fi tted to each individual's data separately, and an obvious BIV was seen: in 4 patients the linear model was adequate, whereas in one patient the Emax model was needed, although no formal model selection was performed. Apparently, the patient with a saturable concentrationresponse profi le differed from others with respect to sensitivity; lower drug concentrations were needed to achieve the maximum response. An advantage of the analysis was the inclusion of baseline QTc in the model; it was estimated together with other PD model parameters. However, a serious drawback was the use of the Bazett correction formula.
The Emax model was fi tted to the mean QTc changes from baseline vs plasma concentrations of disopyramide enantiomers. 45 The linear correction formula was used to derive QTc intervals in 5 healthy subjects; however no individualization was applied. Unbound plasma concentrations of enantiomers were obtained through individual PK modeling and averaged.
In a more recent study of quinidine effects upon intravenous infusion, 46 the linear and sigmoid Emax models were compared, and the latter did not provide better fi t when applied to QTc data. A serious disadvantage of this study was the use of the Bazett correction to obtain QTc values.
(+)-Sotalol effects on QTc intervals in healthy male subjects were analyzed in the work by Uematsu et al. 47 The authors did not report the correction method used. The drug was administered orally and intravenously, and in the latter case PK-PD modeling was attempted. The model included an effect compartment (the equilibration half-life was ~0.6 hours) and was linear with respect to the effect-compartment concentration impact on QTc intervals. Shi et al developed PK and PK-PD models for sematilide effects on QTc intervals. 48 The latter were derived using a linear correction formula similar to Equation 3 without using individualization that downgrades the validity of the analysis results. On the other hand, by contrast to many other investigators, no baseline subtraction prior to modeling was made and the baseline QTc interval was estimated as one of the PD model parameters. Six healthy individuals were assessed, and 3 PD models were compared: a linear one, an Emax model, and a sigmoid Emax model. The model included also an effect compartment to account for a delay in the QTc response. Individual model fi tting was performed using NONMEM software, and it turned out that in 4 individuals the linear model was quite adequate whereas in the remaining 2 subjects, an Emax model was superior. This may be a manifestation of BIV in the maximum effect parameter (E max ). In subjects with higher E max it could not be estimated, and the linear model was appropriate.
Results of PK-PD modeling of QTc interval prolongation after intravenous infusion of dofetilide (0.5 mg over 30 minutes) were reported by Le Coz et al. 49 QT measurements were corrected by using Fridericia formula, and the linear and sigmoid Emax PD models were compared. An equilibration rate constant for the effect compartment was estimated together with the PD parameters after fi tting the model to the individual data of 10 male subjects. In only 2 of them the linear PD model was suffi cient, and in the remaining subjects all parameters of the sigmoid Emax model were estimated with a good precision. The estimated baseline QTcF was 368 ± 11 milliseconds (mean ± SD), the maximum increase was 131 ± 57 milliseconds, and the halfmaximum concentration was 2.2 ± 0.6 ng/mL. The Hill parameter varied substantially between individuals: the range was 1.2 to 6.0 with the mean equal to 2.9 ± 1.8. This study was the fi rst one in which the sigmoid Emax model was used and successfully fi tted to the data of several individuals providing information on drug activity and potency. An obvious disadvantage of the study was the nonindividualized QT correction. QTcB intervals in pediatric patients with supraventricular and ventricular tachyarrhythmia were analysed against steady-state plasma concentrations of a ␤ -blocker sotalol. 50 A linear relationship was observed, and this fi nding was further explored in a population PK-PD study. 51 Two PD models were compared:
where E 0 is the average baseline effect, and C is the drug plasma concentration. The PK model was the 2-compartment with intravenous administration and was developed before simultaneous PK-PD analysis. Final estimates of the PK parameters were obtained simultaneously with the PD parameters. BIV in parameters was modeled using a lognormal distribution. Three models for the residual error in concentrations and QTcB were compared. Finally, the combined additive+proportional error was selected for the PK model and the additive error for the PD model. The comparison of the linear and the Emax PD models (Equation 9 and 10, respectively) did not show any preference of the latter, and the linear one was fi nally selected. Patient sex affected E 0 (it was 17.3 milliseconds higher in females than in males); however, the difference was not signifi cant according to the preselected criterion: objective function decrease by more than 10.8 ( P < .001, df = 1). Other patient characteristics, age in particular, did not infl uence PD parameters. For a typical pediatric patient, the fi nal PD model for QTcB prolongation caused by sotalol was as follows:
The precision of parameter estimates was high (coeffi cient of variation [CV] of 1% and 15% for E 0 and SL, respectively); however, the residual error SD was 19.1 milliseconds, which means high uncertainty about the baseline QTcB (95% prediction interval was 367 -443 milliseconds). The residual error might be overestimated because of the Bazett correction used. Also, an important process inherent to QT and QTc intervals was ignored: a circadian rhythm.
Population PK-PD modeling of azimilide effects on QTc interval in cardiac patients was reported by Phillips et al. 52 The authors did not mention the correction method they used; however, from the other publications on azimilide from the same company, 53 , 54 it may be assumed that it was the Bazett formula (Equation 1). The data of 3 clinical studies were combined for the analysis. The independent variable was the observed azimilide concentration at the time of the QTc measurement, so there was no PK submodel in the PK-PD model. With regard to the PD model, in addition to the linear and Emax models, the sigmoid Emax model was tested. Finally, the Emax model was found to be preferable. BIV in baseline and EC 50 were modeled with an exponential error model. No BIV could be estimated in the E max parameter. The residual variability was modeled with an additive error model. By contrast to the results of the previously mentioned analysis, 51 the sex effect on the baseline QTc interval was signifi cant (392 milliseconds in males and 400 in females). Other signifi cant covariates affecting the baseline were congestive heart failure, paced-artifi cial pacemaker spike, and treatment with digoxin. Only the potassium level in serum had a statistically signifi cant effect on EC 50 . The estimated residual error SD was similar to that in the previously reviewed study 51 : 20.1 milliseconds, or 5% CV. Besides the above mentioned contribution of the suboptimal QT correction and the circadian rhythm, the estimated residual error may also include between-day variability of baseline within a patient (sort of between-occasion variability, BOV).
In a recent study by Bonate 12 PK-PD modeling of the QTcB interval prolongation caused by a noncardiovascular drug was performed. The following covariates were tested: day, period, sex, race, food, baseline serum potassium and calcium levels, and chest lead. Model terms were entered into the model in a linear manner, but the food effect was modeled as an exponential decline from maximal effect. A few models for the drug effect were tested including linear, power, and Emax models. The linear model was deemed the superior one. The data suggest that after controlling for sex, only the dose of medication was an important factor in the QTcB interval prolongation. Simulation was done to characterize the response surface as a function of each of the covariates identifi ed from the population analysis.
All above reviewed studies used model-predicted concentrations as a driving force for the PD response, and this is a common practice in PK-PD modeling. Alternatively, when plasma sampling times are very close to ECG recordings one can use measured concentrations and skip the PK modeling step. There are, however, a few drawbacks in this approach. In particular, during the trial execution some actual sampling times may deviate substantially from scheduled ones. Also, the bioassay may accidentally generate outliers. Both factors will have a negative impact on the precision of PD parameter estimates.
CIRCADIAN RHYTHM IN QT AND QTC
Both RR (or HR) and QT intervals are subject to within-day (circadian) variations. [55] [56] [57] [58] [59] Circadian rhythm is characteristic for QTc as well. [60] [61] [62] [63] [64] [65] [66] Figure 4 shows pooled, individually corrected (as described earlier) QT intervals before treatment vs the clock time in 26 unrelated healthy individuals from the previously presented data. The smoothing line indicates a circadian variation in QTc I with the peak near 10 am.
In general, the statistical signifi cance of the circadian rhythmicity can be documented by the cosinor analysis. 67 , 68 This method characterizes a rhythm by the parameters of a fi tted cosine function or a multi-oscillator function that includes 2 or more cosine functions with different periods. A circadian rhythm model for the QT interval (including the correction) may be represented as follows 31 , 69 : 
In case of 3 oscillators, the fi rst period is 24 hours, the second 12 hours, and the third 6 hours. A 1,i , A 2,i , and A 3,i are individual amplitudes; ⌽ 1,i , ⌽ 2,i , and ⌽ 3,i are acrophase parameters; t is the clock time (t ʦ 0 ÷ 24 hours). When t becomes equal to one of the ⌽ s, the corresponding oscillator reaches its maximum. According to Equation 12 , the amplitudes are fractions of the individual rhythm-adjusted mean baseline QTcm i . The optimal number of the oscillators is selected based on the likelihood. Random BIV can be assumed for all parameters; however, the ability to estimate it is limited by the number of QT interval measurements available and their spread over the day. As it has been mentioned already, the precision of QT interval measurements is low, and a lot of observations are needed to extract a signal coming from the circadian rhythm. The estimation power is improved if all the data (not only pretreatment, but also ontreatment) are combined and a full model that includes also a drug effect module (see below) is fi tted. In this case, not only BIV has to be taken into account, but also BOV at least in QTcm i . This is necessary since in a typical cardiovascular safety study subjects are dosed at different days, which are often separated by long-lasting washout periods.
Examples of circadian variations in QTc I calculated according to Equation 6 are presented in Figure 5 . These values are generated based on the results of the full model fi tted to the entire data set mentioned above, and lines are fi tted curves consisting of 3 cosine functions with amplitude and acrophase parameters estimated via the Bayesian posterior procedure applied to the pretreatment data collected at 2 different study days. Occasions are marked by continuous and dashed lines, and close and open circles, respectively. In 2 subjects (nos. 21 and 23) profi les corresponding to occasions are not discernible, while in the others the difference is quite appreciable, although not as noticeable as BIV. Circadian rhythms in QTc I can be a consequence of internal rhythmic processes and, at least partly, caused by food intakes that occur approximately at the same times of the day. From these fi ndings, it becomes evident that the defi nition of baseline needs modifi cation when the quantitative assessment of the drug effect is concerned. In no case can the predose QTc interval or the mean pretreatment/placebo QTc interval serve as baseline. In the population modeling framework, baseline is an individual within-day QTc I vs time profi le that would be observed if the drug was not given. In order to evaluate baseline properly, the study has to be adequately designed and include at least 2 assessments per individual, one being after placebo.
IMPLEMENTATION OF THE DRUG EFFECT
Thus, Equations 12 and 13 defi ne an individual baseline profi le. To implement a drug effect, a new term, E i , meaning a fractional change in QTc I caused by the drug, is added 31 , 69 :
where
C i is an individual plasma (or effect-compartment) concentration-time profi le predicted by a separate population PK model to be developed before PD modeling. Individual parameters of such a model can be either estimated together with the parameters of the PD model (Equations 14 and 15) in one run, or separately. Both approaches have their pros and cons, which have been discussed elsewhere. 70 The function f can be mechanism-based or just an empirical one depending on available information and on how factors other than the drug effect are described by the entire model. The impact of these factors should be partitioned well enough to allow the use of an appropriate drug effect model. As the goal of a cardiovascular safety study is to assess the QT interval prolongation potential of a drug candidate, one of the preferable PD submodels is the Hill function (sigmoid Emax model):
where C 50,i is a concentration at which the effect is half of its maximum, E max,i , and H i is an exponent. The model represented by Equation 16 describes both activity (E max ) and potency (C 50 ); however it requires a substantial amount of information to estimate the parameters.
In most studies published so far, the linear model was used, and more complex PD models such as the (sigmoid) Emax E617 model were either not tested or did not provide better fi t. The latter might be due to the use of an inadequate correction method, neglecting circadian rhythm, or ignoring BOV in baseline QTc, for example. The result was the increase of the residual error and the lack of the statistical power to estimate more realistic models with a maximum effect parameter. Another problem associated with the (sigmoid) Emax model estimation is that a drug may have low activity/potency (that is good for the compound, but not for modeling). In the case of C 50 being beyond the normal therapeutic range, supratherapeutic doses may be needed.
A possible way to solve (some of) the problems of estimating drug effects on the QT interval is combining data of studies of various compounds with different activity/ potency. In that way the overall power can be enhanced (more subjects included means more observations allowing better assessment of circadian rhythm parameters, correction exponent, and BOV) and more reliable estimates of PD model parameters can be achieved. In particular, a suggestion to include a positive control in the cardiovascular safety study design 9 , 71 has a potential to improve the parameter estimability. However, to apply the population PK-PD method in this case the bioassay of the active comparator should be available.
As it has been mentioned, C i in Equation 16 may stand for plasma or effect-compartment concentration. The drug transport to cardiac tissues may account for the delay as indicated in some studies previously described. 42 , 47 However, the equilibration half-life was short and could be estimated mainly after intravenous administration.
APPLICATION OF THE PK-PD MODEL TO REAL DATA OF QT INTERVAL PROLONGATION
In this section, the results of actual data modeling are briefl y presented. The goal is to provide an illustrative example of how the PK-PD model for drug effects introduced in the previous sections works.
The data have been mentioned previously, and they will be described here in more detail. Two compounds were investigated: A and B. In study I, escalating doses of compound A were given orally to 24 healthy subjects. Each subject received 5 active doses and placebo. Twelve-lead ECG recordings were obtained frequently at each study day. A screening day and a pretreatment day preceded the treatment. An additional " end-of-trial " (posttreatment) day followed the treatment days. Plasma samples for the drug assay were collected at the times close to ECG recordings.
Compound B was investigated in studies II to IV in healthy subjects. All studies were single-dose. Study II was a cardiovascular safety study with frequent ECG recordings. Each individual (25 in total) received 2 active treatments and placebo in a random order at different days. Study III had a similar design; however, only 3 ECG recordings were obtained at each study day. The total number of subjects included was 20. In study IV, each of 24 subjects received either placebo or active treatment with ECGs frequently recorded.
Population PK models for both compounds were developed before PK-PD analysis using concentration-time data collected in studies I to IV. The structural part of the model was common (a 2-compartment linear model with fi rst-order absorption), and individual Bayesian estimates of PK parameters were included in the NONMEM data sets prepared for PK-PD modeling to allow generation of plasma concentrations exactly at the times when ECG was recorded. Data sets of all 4 studies were combined before PK-PD modeling.
Measured RR intervals were included in the data set, and no separate PK-PD modeling for RR intervals was done. This method might introduce some additional uncertainty in the QT interval modeling results; however, the precision of the RR interval measurements are much higher compared with the QT interval since the former is the distance between 2 well-defi ned peaks ( Figure 1 ). The impact of using measured RR intervals instead of model-predicted ones still remains to be explored. Nevertheless, variability in RR intervals caused, for instance, by the circadian rhythm and the potential drug effect is adequately captured when measured intervals are used in PK-PD modeling.
Combining several studies increases the robustness of estimates of non-drug-related parameters that can be called " system parameters " : QTcm, ␣ , amplitudes, and acrophases. Also, the number of cosine functions in the circadian rhythm submodel can be unequivocally identifi ed. In our case, models with 2 and 3 cosine functions were compared. The inclusion of the third cosine with the period of 6 hours resulted in a highly signifi cant improvement of the fi t (the NONMEM objective function value decreased by almost 50). Table 1 gives the summary of estimates of the system parameters. Figure 6 shows some goodness-of-fi t plots.
The mesor baseline parameter, QTcm, differs between males and females and is in line with observations of other researchers. 12 , 51 , 52 While QTcm is subject to random BIV and BOV, no study effect was seen. The correction exponent ␣ varied from individual to individual, but no withinsubject variability was observed; this result is in accordance with the fi ndings of Batchvarov et al. 26 The drug effect submodel had initially 2 pairs of E max and C 50 to account for the potential disparity in the activity and potency between the 2 drugs. No difference in the Hill parameter was assumed. Finally, it turned out that E max for compound B was small, and its statistical signifi cance could not be proven. Thus, only E max and C 50 related to compound A were estimated in the fi nal model, and compound B had no effect. Also an attempt has been made to include the effect compartment in the PK-PD model; however, no improvement of the fi t was obtained.
Estimated residual error CV was lower compared with the estimates reported by the authors who performed population PK-PD modeling of QT interval data: 2.8% vs 5%. 51 , 52 The reduction of the residual error was evidently the result of inclusion of the circadian rhythm and BOV in the model, and also of the individualized QT interval correction.
For the graphical presentation of the concentration-effect relationship, the observations were corrected to eliminate variability caused by both RR intervals and the circadian rhythm. Therefore the correction was slightly different from that by Equation 6 . It was based on model Equation 14 , and is shown below: Figure 7 shows how QTc I * derived via Equation 17 depend on the plasma concentration. Figure 8 gives examples of individual fi ts for subjects, in which suffi ciently high plasma concentrations were achieved and full effect could be observed. The estimates of drug-effect-related parameters are summarized in Table 2 .
For this particular analysis, compound A can be considered as a positive control for compound B, which demonstrated a negligible effect. No sex difference in the E max parameter was found; however, due to higher QTcm in females ( Table  1 ) , the maximum absolute drug effect for a typical female and male is different: 414 and 399 milliseconds, respectively, meaning that females were at slightly higher risk of prolonged QTc intervals. There was also a small difference in terms of changes from baseline: 25 and 24 milliseconds for a typical female and male, respectively, although this difference was not statistically signifi cant.
The ICH Preliminary Concept Paper 9 provides the following limits to be taken into account when analyzing QT/QTc interval prolongation data: 
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Absolute QTc interval prolongation (milliseconds):
• QTc interval > 450
• QTc interval > 480
• QTc interval > 500
Change from baseline in QTc interval (milliseconds):
• QTc interval increases from baseline ≥ 30
• QTc interval increases from baseline ≥ 60
These limits should be applied to individual estimates, not to typical values that do not say anything about individual safety. BIV in E max is high (55%, Table 2 ), and there may be subjects with the maximum QTc I prolongation substantially exceeding the typical value. This is illustrated by Figure 9 , which shows histograms of individual maximal QTc I derived via Equation 6 , and changes from baseline ( ⌬ QTc I ) calculated on the basis of Bayesian parameter estimates. Note that variability coming from the circadian rhythm is preserved in this computation. Also, results of simulation based on the model (1000 individuals, equal proportion of males and females) are presented in the same fi gure in the form of empirical densities. In Figure 9 , the upper 2 panels present subjects participating in the study of compound A. The bottom panels show histograms of maximal QTc I and ⌬ QTc I calculated for subjects receiving compound B; simulated densities thus do not include any drug effect. Circadian variability is nevertheless taken into account, and it results in ⌬ QTc I shifted toward positive values. They, however, do not exceed 20 milliseconds. Figure 9 clearly demonstrates that compound A may cause the QTc I interval prolongation beyond the above-mentioned limits in some subjects, and the fraction of subjects is especially high in case of ⌬ QTc I ( Table 3 ). 
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The preceding considerations concern the maximum QTc I response that can only be observed at the plasma concentrations above 200 ng/mL (see Figure 7 ) . The steepness of QTc I -C relationship is quite high (Hill parameter H is ~7, Table 2 ), and compound A is safe both in males and females unless plasma concentration exceeds 70 ng/mL. Note that due to sex disparities in the potency (C 50 ), safety margins are narrower in females compared with males ( Figure 7 ). While on average there is almost no QTc I prolongation in males at 100 ng/mL, this level may produce ~50% of maximum effect in females.
PK-PD MODELING AND THE STANDARD BIOSTATISTICAL ANALYSIS OF CARDIOVASCULAR SAFETY DATA
The ICH Preliminary Concept Paper 9 provides an overview of methods that are recommended to assess the cardiovascular safety of drugs. According to this document, the QT/QTc interval data should be presented both as analyses of central tendency (eg, means, medians) and categorical analyses.
The effect of an investigational drug on the QT/QTc interval is most commonly analyzed using the largest time-matched mean difference between the drug and placebo (baselinesubtracted) over the collection period (eg, hourly, weekly, monthly). Additional approaches to the assessment of central tendency could include the analysis of time-averaged QT/QTc intervals or the analysis of changes occurring at the plasma concentration peak (C max ) for each individual. This approach (herein referred to as standard) has an advantage of not using sophisticated statistical tools and specialized software. However, the traditional evaluation has many defi ciencies, some of which are summarized below:
1. It provides no quantitative information on the QT prolongation triggered by a drug either in terms of activity or potency. Thus the standard approach may have its value for regulatory purposes but is not suffi cient for drug development in which the usual goal is estimating activity and potency of a compound, and evaluating safety margins.
2. Moreover, it seems that most complications and fatal events potentially related to QT/QTc interval prolongation occurred either after taking supratherapeutic doses of drugs or as a consequence of co-administration of potent metabolic inhibitors. By contrast to the standard approach that only assesses the extent of prolongation at the peak of actual plasma concentration, the model-based method enables the estimation of the ultimate QT prolongation potential (ie, E max ) of a drug and the testing (through simulation) of various scenarios, which cannot be investigated in clinical studies with healthy subjects.
3. Time-averaging substantially reduces the sensitivity of the test.
4. Due to BIV of PK profi les the time to C max may differ substantially between individuals, and the sampling times selected based on mean profi les can miss the true C max for substantial proportion of subjects resulting in underestimating of the actual magnitude of QT/QTc prolongation. This problem is especially important in case of immediaterelease oral formulations with sharp plasma concentration peaks. 
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5. Baseline subtraction inevitably leads to at least doubling the variance of the difference compared with that of original values and reduces the power of any test for the drug effect.
Categorical analyses of QT/QTc interval data as suggested by the ICH Preliminary Concept Paper are based on the number and percentage of patients meeting or exceeding some predefi ned upper limit value. 9 Clinically noteworthy QT/QTc interval signals might be defi ned in terms of absolute QT/QTc intervals or changes from baseline. Absolute interval signals are QT/QTc interval readings in excess of some specifi ed threshold value. Separate analyses should be provided for patients with normal and elevated baseline QT/ QTc intervals. Categorical analyses are most informative when it is possible to compare the rate of suprathreshold readings in the treatment and control groups. 9 Thus, the categorical analysis is bound to raw measurements to an even bigger extent than the analysis based on the central tendency. Taking into account the fact that the random variability of QT measurements is high as shown previously, and outlying measurements are quite common, the categorical analysis is associated with a high chance of false-positive or false-negative outcome, especially if the number of subjects included in a " thorough QT/QTc study " is relatively low.
More advanced metrics were suggested and compared with the standard ones through clinical trial simulation. 72 , 73 It has been shown that the most sensitive metric is the area under QTc-time curve with baseline QTc as a covariate.
By contrast to the standard approach based on raw measurements, population modeling (when correctly applied) not only gives answers to the question of safety, but also provides quantitative information on the drug activity and potency. The inference with respect to the central tendency is based on well-grounded criteria such as the likelihood ratio test and parametric and nonparametric confi dence intervals. The model-based approach is by defi nition much more robust with respect to outliers compared with the standard methods. Through simulation the risks of exceeding safety thresholds in the population (an analog of the categorical analysis) can be easily assessed. Bonate 12 also showed how the false-positive rate in a study can be determined through Monte Carlo simulation.
An essential condition for activity/potency estimation via population PK-PD modeling is using suffi ciently high doses to ensure that the concentration achieved allows estimating a maximum response. On the other hand, if maximum concentration is not high enough, simpler PD models can be used instead of the (sigmoidal) Emax model. Of importance, however, is that any model having no maximum effect parameter can only be employed to establish safety margins of the drug and is only applicable within the concentration range studied. No extrapolations beyond this range can be made as this will inevitably lead to the overestimation of the cardiovascular risk. In fact, if a particular study revealed the fact of QT/QTc prolongation but failed in the estimation of the maximum response, another study would have to be conducted with increased doses or with the use of potent metabolic inhibitors as recommended in the ICH Preliminary Concept Paper. 9 It is expedient to initialize such a study after establishing the dose range to be used in clinical practice (thus, after phase 2B).
Population modeling allows effi cient combining of 2 or more studies thereby increasing the overall power. Studies to be combined may have completely different designs; in particular, safety studies in which subjects are frequently assessed can be combined with phase 2 studies with sparse blood sampling and ECG recording. In this way the cardiovascular safety in the target patient population can be effectively assessed. Separate analysis of sparse PK-PD data without supportive information that is only available in well-controlled phase 1 studies is hardly feasible.
The ICH Preliminary Concept Paper suggests using a positive control (a drug known to prolong the QT/QTc interval) " to establish assay sensitivity. " 9 The usefulness of the positive control may be substantially increased if the design of a thorough QT/QTc study includes plasma concentration assay of the active comparator together with the drug of interest followed by an extensive PK-PD modeling. Such an approach will increase the trustworthiness of the study results.
CONCLUSION
While the degree of QT interval prolongation is recognized as an imperfect biomarker for the proarrhythmic risk, there is at least a qualitative relationship between QT prolongation and the risk of TdP, especially for drugs that cause substantial prolongation of the QT/QTc interval. In this review, factors affecting the QT interval and the methods that are currently in use in the analysis of drug effects on the QT interval duration were overviewed with the emphasis on population PK-PD modeling.
Due to multiple sources of variability and potentially low precision of QT measurements resulting in a low signalto-noise ratio, the standard approach based on the raw observations and formal statistics may lead to false-positive or false-negative conclusions, especially when the individual risk is concerned. Population PK-PD modeling offers a potent tool to split the overall variability into components and to estimate them. In the literature, however, there are only a few publications in which population PK-PD modeling is applied to QT interval prolongation data.
A comprehensive PK-PD model is introduced that incorporates an individualized QT interval correction, a circadian rhythm in baseline QTc I , and a drug effect. Using this model may solve at least some of the problems inherent in the standard analysis methods and also provide a basis for simulation that may help in designing better cardiovascular safety trials.
